Anavex 2-73 Receives the FDA's Orphan Drug Designation (ODD)

May 20, 2016

We recently told you about positive research results stemming from our collaboration with Anavex in the Rettsyndrome.org Scout Program.  We are now even more pleased to share the news that Anavex announced that their compound Anavex 2-73 has received the FDA’s Orphan Drug Designation (ODD).  This designation gives Anavex incentives as they continue down the path of drug development of Anavex 2-73 for the treatment of Rett syndrome.  Rettsyndrome.org is excited for this new development and will continue to partner with Anavex in hopes to bring Anavex 2-73 towards clinical trials.

Read Anavex's press release.
Read more about Anavex 2-73 and the Scout Program.
Learn more about what Orphan Drug status means.